SCHEMBL208500

SCHEMBL208500

C=C(C)OC(=O)Nc1nccs1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.55
RAB9A P51151 5/20 0.51
NPC1 O15118 5/20 0.51
PPARG P37231 1/20 0.51
NCOR2 Q9Y618 1/20 0.51
HTT P42858 1/20 0.51
ALDH1A1 P00352 1/20 0.51
PKM P14618 1/20 0.51
MEN1 O00255 1/20 0.50
MAPT P10636 1/20 0.50
KMT2A Q03164 1/20 0.50
HSD17B10 Q99714 1/20 0.49
AGER Q15109 1/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
ALOX15 P16050 1/20 0.47
MAPK1 P28482 1/20 0.47
STAT1 P42224 1/20 0.47
LMNA P02545 1/20 0.47
TP53 P04637 1/20 0.47
TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL628283 0.81 L3MBTL1 (0.62) L3MBTL1RAB9ANPC1PPARGNCOR2
SCHEMBL9715384 0.80 HTT (0.61) L3MBTL1RAB9ANPC1PPARGNCOR2
Acetic Acid Methyl Ester SCHEMBL10387561 0.78 AGER (0.59) L3MBTL1RAB9ANPC1PPARGNCOR2
SCHEMBL13075600 0.77
SCHEMBL115951 0.77
SCHEMBL797018 0.77 SMN1; SMN2 (0.61) L3MBTL1RAB9ANPC1PPARGNCOR2
Hydrochloric Acid SCHEMBL29059238 0.75 AGER (0.64) L3MBTL1RAB9ANPC1PPARGNCOR2
Hydrochloric Acid SCHEMBL28995499 0.75 AGER (0.64) L3MBTL1RAB9ANPC1PPARGNCOR2
SCHEMBL13525912 0.75 L3MBTL1 (0.56) L3MBTL1RAB9ANPC1PPARGNCOR2
SCHEMBL8366793 0.75 PKM (0.74) L3MBTL1RAB9ANPC1PPARGNCOR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1963315-B1 ENZYME INHIBITORS CANCER REC TECH LTD (GB) 2014-10-08 EP disclosed
US-8088761-B2 Enzyme inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2012-01-03 US disclosed
US-20090247507-A1 Enzyme Inhibitors THE INSTITUTE OF CANCER RESEARCH (GB) 2009-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247507-A1 Enzyme Inhibitors AURKC, AURKB, AURKA L3MBTL1 1773/4885RAB9A 3768/4885NPC1 2210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.